NCT05645718

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Name: Clinical Trial NCT05645718
Creator: M.D. Anderson Cancer Center
Keywords: Leukemia, Cyclophosphamide, Phase 2, drug, clinical trial, United States of America

Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center·Phase 2·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Leukemia
Drug/Device/Intervention: Cyclophosphamide
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: M.D. Anderson Cancer Center
Location: Houston, United States of America

Timeline & enrollment

Phase: Phase 2
Start date: Apr 30, 2023
End date: Dec 31, 2029
Enrollment: 27 participants

Primary outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Summary

To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.

ICD-10 classifications

Leukaemia, unspecifiedMyeloid leukaemiaMyeloid leukaemia, unspecifiedOther myeloid leukaemiaMonocytic leukaemia, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05645718
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05645718 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Leukemia. Target enrollment is 27 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.